Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hang Quach

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Journal of Hematology & Oncology|April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaMaria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
Blood Advances|August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsMaria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
Haematologica|September 22, 2018
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTORAndrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
The New England Journal of Medicine|May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of TherapyCyrille Touzeau, Roberto Mina, Hang Quach, et al.
Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.
The Lancet. Oncology|March 4, 2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Shaji K Kumar, Jesús San Miguel, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Journal of Hematology & Oncology|April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaMaria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
Blood Advances|August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsMaria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
Haematologica|September 22, 2018
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTORAndrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
The New England Journal of Medicine|May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of TherapyCyrille Touzeau, Roberto Mina, Hang Quach, et al.
Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.
The Lancet. Oncology|March 4, 2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Shaji K Kumar, Jesús San Miguel, et al.
Pageof 12